Identifying the unknown PFAS profile in firefighting foams/AFFF

Sep 17, 2021 | Blogs, Environmental / Industrial | 0 comments

Read time: 2 minutes

According to a recent study from Harvard University, the US EPA, and NIEHS, traditional targeted analysis techniques poorly characterize the PFAS composition of contemporary PFAS-based firefighting foams, know as aqueous film-forming foams (AFFF).  Using the EPA 533 PFAS drinking water method for the analyte list, the researchers found that targeted mass spectrometry methods accounted for <1% of organic fluorine content.  This is important because it demonstrates that targeted analysis methods miss nearly all the PFAS compounds in modern AFFF mixtures, thus underestimating the risk to human health and the environment.

In the second episode of PFAS Fireside chats, the lead author, Bridger Ruyle, joined me to discuss the study’s main findings and implications.  Bridger is a PhD student in Environmental Science and Engineering at the Harvard John A. Paulson School of Engineering and Applied Science.        

The study examined both legacy and modern commercial AFFF mixtures.  AFFF are used to combat petroleum-based fires by creating a barrier between the fire and air, and they are they used extensively at airports and by the military around the globe. 

If targeted analytical methods don’t adequately capture all the PFAS compounds in a sample, how did the researchers know what they were missing?  First, the researchers used techniques such as “extractable organofluorine (EOF)” to quantify the total potential PFAS compounds in the AFFF mixtures.  That is how they showed their targeted methods were missing a substantial portion of the PFAS.  Next, they used high-resolution accurate mass spectrometry to identify the unknown PFAS. 

So, what’s in these modern AFFF mixtures?  It turns out that >90% of the PFAS compounds are 6:2 fluorotelomer-based compounds.  While the exact fate of these isn’t well understood, they could potentially degrade to very persistent PFAS compounds, several of which are covered by various state and federal regulations.

The study focused on commercial AFFF mixtures, but what does it look like in the real-world environment where AFFF releases have impacted the surface and groundwater?  Bridger and his colleagues addressed that question in a follow-up paper, and perhaps we will talk about it in a future episode of PFAS Fireside chats.

RUO-MKT-18-13829-A

Understanding PFAS and its impact on U.S. drinking water

In recent years, per- and polyfluoroalkyl substances (PFAS), often referred to as “forever chemicals,” have become a growing topic of interest due to their persistence in the environment and potential health risks. These synthetic compounds have been widely used in various industrial applications and consumer products since the 1940s. PFAS can be found in the air, soil, and water, and studies have shown that most people have detectable levels of PFAS in their bloodstream. One of the main exposure pathways for humans is through drinking water, particularly in communities located near industrial sites, military bases, or areas where firefighting foam has been used.

Selecting an LC-MS system for quantitation of pharmaceutical drug development

We understand you are busy, needing to prioritize running instruments, reporting results and managing your laboratory to meet deadlines. We created a solution guide to explain how SCIEX systems fit in the drug development pipeline to save you time evaluating options.

Nitrosamines: Where are we now?

Nitrosamines are a large group of N-nitroso compounds that share a common functional N-N=O group. They are produced by a chemical reaction between a nitrosating agent and a secondary or tertiary amine. Back in 2018, nitrosamines suddenly found themselves in the spotlight when they were unexpectedly detected in medications for high blood pressure. Since then, they have been found in several other prescription medications, including those for heartburn, acid reflux and diabetes, resulting in manufacturers recalling some common medications.

Posted by

Craig has worked in the mass spectrometry industry for over 20 years and has been with SCIEX since 2016. As a senior product application specialist, he works with customers to understand their targeted screening workflows and provide solutions using high-resolution accurate mass spectrometry technologies.

0 Comments

Submit a Comment

Wordpress Social Share Plugin powered by Ultimatelysocial